Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:35:21.728Z.
Calculation as of: 2026-10-06T13:35:21.728Z.
Quote observation: 2026-10-06T13:34:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5c9508078213b28dfeff6809371853141f28b2786ea2d18fc4f82dd6840af9a4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Advanced Biomed Inc. Common Stock
Market Cap
$9.14M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$8.91M
Price/FCF Ratio
N/A
TTM Avg
9.96
3Y Avg
9.96
5Y Avg
9.96
Market Cap
$9.88M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Advanced Biomed Inc. Common Stock (ADVB) | $9.14M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.91M | N/A | 9.96 | 9.96 | 9.96 |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.26M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.18M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.96M | N/A | N/A | N/A | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.75M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $8.02M | N/A | N/A | N/A | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.88M | N/A | N/A | N/A | N/A |
| Ainos, Inc. (AIMD)vs › | $9.94M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.61M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
